Device Trial Radar · NCT04545619
Performance of QDOT Micro™ Catheter With nGEN Generator for Patients With AFIB.
Last checked: Nov 20, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Oct 2, 2020
Primary completion
Nov 9, 2021
Study completion Nov 9, 2021
Sponsor
- Lead sponsor
- Biosense Webster, Inc.Public (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 11, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This workflow study will further evaluate the acute performance and safety of the QDOT MICRO™ catheter in a clinical setting used in combination with nGEN Generator. Subjects will be followed for 7 days post procedure.
Conditions
- Atrial Fibrillation
Interventions
QDOT MICRO SystemDevice
QDOT Micro Catheter with nGEN Generator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Achieved Acute Procedural SuccessTime frame: Up to 104 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut de Cardiologie de Montréal (Montreal Heart Institute)
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.